Advertisement

Advertisement

News

Treatment Algorithm for Patients With Myeloma and Light Chain Cast Nephropathy

News

FDA Approves Epcoritamab-bysp in Treatment of Resistant DLBCL

News

Advanced Biliary Tract Cancer: Is Durvalumab Plus Chemotherapy a Cost-Effective Treatment in China?

News

Predicting Benefit of Elotuzumab in Myeloma: Novel Scoring System Focuses on Lymphocyte Counts and B2M

Medical Literature

Using RNA-Sequencing Data to Establish a Prognostic Model for Bladder Cancer

Medical Literature

How Lenvatinib Compares With Other Therapies for Nonviral, Unresectable Liver Cancer

News

AACR 2023: Phase III AEGEAN Trial of Durvalumab-Based Therapy Meets Primary Endpoints in Resectable NSCLC

Glenn Hanna, MD, on Using Checkpoint Inhibitors for Head and Neck Cancer

Daniel P. Petrylak, MD, on Enfortumab Vedotin-ejfv as Monotherapy for Bladder Cancer

View More

Advertisement

JNCCN Spotlights

(UPDATE) Pembrolizumab (NSCLC)

Elotuzumab

(UPDATE) Pertuzumab (Breast Cancer)

View More

More

News

AACR 2023: Checkpoint Blockade and Multiple Myeloma–Specific Targeting May Enhance NK Cell Responses

Advanced Biliary Tract Cancer: Is Durvalumab Plus Chemotherapy a Cost-Effective Treatment in China?

RNA Modification and Tumor Immunity in Lung Cancer: Predicting Outcomes With Neoadjuvant Immunotherapy

AACR 2023: Combination of MET and PD-1 Inhibitors Under Study in Liver Cancer

FDA Approves Polatuzumab Vedotin in Combination Therapy for B-Cell Lymphomas

How Lenvatinib Compares With Other Therapies for Nonviral, Unresectable Liver Cancer

Using Molecular Subtyping to Predict Response to Immunotherapy in Urothelial Cancer

R-CHOP as Front-Line Therapy for Primary Mediastinal LBCL: A View From Jordan

View More

Advertisement

Published

Medical Literature

Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study

Combination Treatment With or Without Transplantation in Multiple Myeloma

Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

View More

Ongoing

CE Activities

Exploring the Current and Future Role of BCMA-Directed Therapy in the Management of Multiple Myeloma

Similarities and Differences in the Efficacy of Neoadjuvant and Adjuvant Immunotherapies for Localized NSCLC

Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma With Anti–PD-1/PD-L1 Agents

Tumor Mutational Burden, Neoantigens, and a Pathway to Predicting Response to Checkpoint Inhibitors

View More

Available

Clinical Trials

A Study to Learn About the Effects of the Combination of Elranatamab

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced NSCLC

A Phase III, Randomized, Placebo-Controlled Clinical Study of SBRT With or Without Pembrolizumab in Participants With Medically Inoperable NSCLC (KEYNOTE-867)

View More

Resources

For Your Patients

ONS Immunotherapy News

ONS Immunotherapy Community

Society for Immunotherapy of Cancer Patient Resources

CancerCare on Immunotherapy

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.